Cadenza Bio is developing highly selective Estrogen Receptor β (ERβ) targeting small-molecule compounds aimed at promoting remyelination for patients with Multiple Sclerosis. The company intends to use its recent financing to advance therapeutic drug development programs focused on remyelination. Cadenza holds an exclusive license to technology originating from an academic collaboration between researchers at the University of Illinois Urbana‑Champaign and the University of California, Riverside. Its programs were launched in 2022 through a partnership between SmartHealth Catalyzer (Chicago) and Ascend BioVentures (Oklahoma City). The company notes partial prior funding from the National Multiple Sclerosis Society’s Fast Forward commercial research program. Cadenza is led by CEO Carol Curtis and is based in Oklahoma City, OK.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2023